These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34866012)

  • 1. Incidence of breast cancer in people with cystic fibrosis: A cause for concern?
    FitzMaurice TS; Nazareth DS
    J Cyst Fibros; 2022 Sep; 21(5):890. PubMed ID: 34866012
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators.
    Shaw N; Collins S; Smith T; McCulloch A; Ketchell I; Edwards V; Blaikie L; Daniels T
    Br J Hosp Med (Lond); 2021 Nov; 82(11):1-6. PubMed ID: 34817261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ELX/TEZ/IVA use in cystic fibrosis liver disease: Is the perspective of improved lung function worth the risk?
    Gardiner A; Volovets A; Haber P; Jo H; Visser S; Yozghatlian V; Taylor N; Nolan S; Dentice R; Malouf M; Marinelli T; Sivam D
    J Cyst Fibros; 2022 Sep; 21(5):881-884. PubMed ID: 35760705
    [No Abstract]   [Full Text] [Related]  

  • 4. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
    Sergeev V; Chou FY; Lam GY; Hamilton CM; Wilcox PG; Quon BS
    Ann Am Thorac Soc; 2020 Feb; 17(2):147-154. PubMed ID: 31661636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del.
    Beswick DM; Humphries SM; Balkissoon CD; Strand M; E Miller J; Khatiwada A; Vladar EK; Lynch DA; Taylor-Cousar JL
    Int Forum Allergy Rhinol; 2022 Jul; 12(7):963-966. PubMed ID: 34908251
    [No Abstract]   [Full Text] [Related]  

  • 7. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic Fibrosis-Asthma Overlap Syndrome. Combination of Cystic Fibrosis Transmembrane Conductance Regulator Modulators and Type 2 Targeted Biologic Treatment for Asthma.
    Jiménez-Gómez M; Díaz Campos RM; Diab Cáceres L
    Arch Bronconeumol; 2023 Aug; 59(8):512-513. PubMed ID: 37127448
    [No Abstract]   [Full Text] [Related]  

  • 10. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new era has dawned for persons with cystic fibrosis; however many knowledge gaps exist in our efforts to improve care.
    Hadjiliadis D; Clausen ES
    J Cyst Fibros; 2022 May; 21(3):383-384. PubMed ID: 35437232
    [No Abstract]   [Full Text] [Related]  

  • 12. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
    Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
    Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of CFTR modulators 2020.
    Goetz DM; Savant AP
    Pediatr Pulmonol; 2021 Dec; 56(12):3595-3606. PubMed ID: 34407318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
    Bitonti M; Fritts L; So TY
    J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing life expectancy in cystic fibrosis: Advances and challenges.
    McBennett KA; Davis PB; Konstan MW
    Pediatr Pulmonol; 2022 Feb; 57 Suppl 1(Suppl 1):S5-S12. PubMed ID: 34672432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CFTR Modulator Therapy for Cystic Fibrosis.
    Grasemann H
    N Engl J Med; 2017 Nov; 377(21):2085-2088. PubMed ID: 29099349
    [No Abstract]   [Full Text] [Related]  

  • 18. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celiac Disease in Patients With Cystic Fibrosis on Ivacaftor: A Case Series.
    Hjelm M; Shaikhkhalil AK
    J Pediatr Gastroenterol Nutr; 2020 Aug; 71(2):257-260. PubMed ID: 32304549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
    Trimble AT; Donaldson SH
    J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.